z-logo
open-access-imgOpen Access
Vancomycin‐Resistant and Vancomycin‐Susceptible Enterococcal Bacteremia: Comparison of Clinical Features and Outcomes
Author(s) -
Gregory M. Lucas,
Noah Lechtzin,
D. Wonder Puryear,
Linda Yau,
Charles Flexner,
Richard D. Moore
Publication year - 1998
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/520311
Subject(s) - bacteremia , medicine , vancomycin , enterococcus , metronidazole , vancomycin resistant enterococcus , risk factor , intensive care medicine , antibiotics , microbiology and biotechnology , staphylococcus aureus , genetics , bacteria , biology
Vancomycin-resistant Enterococcus (VRE) is a major nosocomial pathogen. We collected clinical and laboratory data on 93 hospitalized adults with VRE bacteremia and 101 adults with vancomycin-susceptible enterococcal (VSE) bacteremia. Risk factors for VRE bacteremia included central venous catheterization, hyperalimentation, and prolonged hospitalization prior to the initial blood culture. VRE-infected patients were less likely to have undergone recent surgery or have polymicrobial bacteremia, suggesting a pathogenesis distinct from traditional VSE bacteremia. Prior exposure to metronidazole was the only significant pharmacologic risk factor for VRE bacteremia. Animal studies suggest metronidazole potentiates enterococcal overgrowth in the gastrointestinal tract and translocation into the bloodstream. An increasing APACHE II score was the major risk factor for death in a multivariate analysis, with VRE status being of only borderline significance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom